Join the Diskets group to help and get support from people like you.
Diskets News
Hospital Addiction Consultation Service Aids Opioid Use Disorder
WEDNESDAY, April 16, 2025 – A hospital-based addiction consultation service can improve receipt of evidence-based treatment for people with opioid use disorder (OUD), according to a study published...
Methadone Tied to Lower Risk for Discontinuation Versus Buprenorphine/Naloxone
FRIDAY, Oct. 18, 2024 – Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with buprenorphine/naloxone, according to a study...
Inmates in Many U.S. Jails Have No Access to Meds That Fight Opioid Addiction
TUESDAY, Sept. 24, 2024 – Opioid use disorder can be a contributing factor to Americans landing in the nation's prisons and jails, but those inmates typically have no access to medications that...
FDA Medwatch Alert: Opioid Addiction Medications in Patients Taking Benzodiazepines or CNS Depressants: Drug Safety Communication - Careful Medication Management Can Reduce Risks
ISSUE: Based on additional review, FDA is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Medwatch Alert: Compounded Drugs Stored in Becton-Dickinson (BD) 3 ml and 5 ml Syringes: FDA Warning - Do Not Use
ISSUE: FDA is alerting health care professionals not to administer to patients compounded or repackaged drugs that have been stored in 3 milliliter (ml) and 5ml syringes manufactured by...
FDA Medwatch Alert: Methadone Hydrochloride (dolophine)
Indication: Treatment of moderate to severe pain not responsive to non-narcotic analgesics; detoxification of opioid addiction; and maintenance treatment of opioid addiction [Posted 11/27/2006] FDA...
FDA Medwatch Alert: Dolophine (methadone hydrochloride)
Indication: Treatment of moderate to severe pain not responsive to non-narcotic analgesics; detoxification of opioid addiction; and maintenance treatment of opioid addiction[Posted 11/27/2006] FDA...
Further information
Related condition support groups
Chronic Pain, Opiate Withdrawal, Pain